Spruce Biosciences, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $40.84
- 52-Week Range
- $38.06 – $115.00
- Market Cap
- $116.37M
- P/E (TTM)
- —
- EPS (TTM)
- -33.29
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.76
- PEG Ratio
- —
- Return on Equity
- -187.35%
- Return on Assets
- -54.17%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 4.83
- Debt/Equity
- 0.13
- Total Debt
- $8.32M
- Free Cash Flow
- $-18.05M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $37.00M
Market Snapshot
About
Spruce Biosciences is a biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is advancing tildacerfont, an investigational therapy for patients with congenital adrenal hyperplasia, a rare genetic disorder affecting cortisol production.